CorMedix Inc. (CRMD)
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Are Investors Undervaluing CorMedix (CRMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
Why CorMedix Could be the Biopharma Name to Watch Early in 2026
An often overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, presenting a significant complication and an unmet medical need.
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
The mean of analysts' price targets for CorMedix (CRMD) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating
CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.
